港股異動丨微創醫療漲逾6% 旗下科創板公司心脈醫療首三季多賺48%
格隆匯10月28日丨微創醫療(0853.HK)漲逾6%,報8.1港元,成交3343萬港元,總市值131億港元。

首批登陸科創板的上市公司心脈醫療昨日發佈2019年三季度報告,今年前三季度,公司實現營業收入2.48億元,同比增長43%;歸屬於上市公司股東的淨利潤1.13億元,同比增長48%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.02億元,同比增長43%;基本每股收益1.94元。公開資料顯示,心脈醫療系微創醫療的下屬子公司,主要從事主動脈及外周血管介入醫療器械的研發、生產和銷售,主營產品為大動脈覆膜支架系統、術中支架系統、大球囊及周圍血管支架等產品。微創醫療創始人、董事局主席常兆華曾表示,心脈醫療就是微創醫療所生產出的“公司產品”,是第一個比較成熟的、能夠走向市場的產品。未來可能還會有很多類似的產品,等壯大了就逐一放出去。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.